It has been shown that recurrent glioblastomas after temozolomide treatment frequently exhibit a hypermutated phenotype with defective MMR [56] confirming previous preclinical evidence that MMR defects are a major mechanism of resistance to temozolomide [38]. The gene discussed is MRC1; the disease is glioblastoma.